Common Contracts
2 similar Collaboration and License Agreement contracts by Kiniksa Pharmaceuticals, Ltd.
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 5th, 2022 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “Agreement”) is made as of February 21, 2022 (the “Effective Date”) by and between Kiniksa Pharmaceuticals (UK), Ltd., a United Kingdom corporation (“Kiniksa”), having a place of business at Third Floor, 23 Old Bond Street, London, United Kingdom, W1S 4PZ, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (“Partner”), having a place of business at No. 866 Moganshan Road, GongShu District, Hangzhou City, Zheijiang Province, People’s Republic of China. Kiniksa and Partner are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 5th, 2022 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “Agreement”) is made as of February 21, 2022 (the “Effective Date”) by and between Kiniksa Pharmaceuticals (UK), Ltd., a United Kingdom corporation (“Kiniksa”), having a place of business at Third Floor, 23 Old Bond Street, London, United Kingdom, W1S 4PZ, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (“Partner”), having a place of business at No. 866 Moganshan Road, GongShu District, Hangzhou City, Zheijiang Province, People’s Republic of China. Kiniksa and Partner are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
